ZIOPHARM ONCOLOGY INC (ZIOP) Stock Price, Quote, News and Overview
NASDAQ:ZIOP - Nasdaq - Common Stock
ZIOP Quote, Performance and Key Statistics
0.8657
-0.01 (-0.88%)
The current stock price of ZIOP is 0.8657 null. In the past month the price decreased by -22.01%. In the past year, price decreased by -76.67%.
ZIOP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 326.93B | ||
| AMGN | AMGEN INC | 13.23 | 147.65B | ||
| GILD | GILEAD SCIENCES INC | 14.05 | 135.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.50B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.8 | 66.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.66B | ||
| ARGX | ARGENX SE - ADR | 98.44 | 35.28B | ||
| ONC | BEIGENE LTD-ADR | 5.87 | 25.45B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.35B | ||
| NTRA | NATERA INC | N/A | 20.96B | ||
| BIIB | BIOGEN INC | 8.22 | 19.06B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.94B |
Related stock screener links
About ZIOP
Company Profile
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2004-08-20. The firm is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Company Info
ZIOPHARM ONCOLOGY INC
One First Avenue, Parris Building 34, Navy Yard Plaza
Boston MASSACHUSETTS 02129 US
CEO: Heidi Hagen
Employees: 103
Phone: 16172591970.0
ZIOPHARM ONCOLOGY INC / ZIOP FAQ
What is the stock price of ZIOPHARM ONCOLOGY INC today?
The current stock price of ZIOP is 0.8657 null. The price decreased by -0.88% in the last trading session.
What is the ticker symbol for ZIOPHARM ONCOLOGY INC stock?
The exchange symbol of ZIOPHARM ONCOLOGY INC is ZIOP and it is listed on the Nasdaq exchange.
On which exchange is ZIOP stock listed?
ZIOP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZIOPHARM ONCOLOGY INC stock?
13 analysts have analysed ZIOP and the average price target is 4 null. This implies a price increase of 361.48% is expected in the next year compared to the current price of 0.8657. Check the ZIOPHARM ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZIOPHARM ONCOLOGY INC worth?
ZIOPHARM ONCOLOGY INC (ZIOP) has a market capitalization of 187.12M null. This makes ZIOP a Micro Cap stock.
How many employees does ZIOPHARM ONCOLOGY INC have?
ZIOPHARM ONCOLOGY INC (ZIOP) currently has 103 employees.
What are the support and resistance levels for ZIOPHARM ONCOLOGY INC (ZIOP) stock?
ZIOPHARM ONCOLOGY INC (ZIOP) has a resistance level at 0.88. Check the full technical report for a detailed analysis of ZIOP support and resistance levels.
Should I buy ZIOPHARM ONCOLOGY INC (ZIOP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZIOP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZIOP, evaluating the profitability, health, valuation and growth aspects
- ZIOPHARM ONCOLOGY INC (ZIOP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZIOPHARM ONCOLOGY INC (ZIOP) Sales and EPS estimates to see what analysts future expectations are.
- ZIOPHARM ONCOLOGY INC (ZIOP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZIOPHARM ONCOLOGY INC (ZIOP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZIOPHARM ONCOLOGY INC (ZIOP) Stock Chart to make your own analysis
- ZIOPHARM ONCOLOGY INC (ZIOP) Latest news and press-releases to stay up to date.
Does ZIOPHARM ONCOLOGY INC (ZIOP) stock pay dividends?
ZIOP does not pay a dividend.
When does ZIOPHARM ONCOLOGY INC (ZIOP) report earnings?
ZIOPHARM ONCOLOGY INC (ZIOP) will report earnings on 2022-03-04, after the market close.
What is the Price/Earnings (PE) ratio of ZIOPHARM ONCOLOGY INC (ZIOP)?
ZIOPHARM ONCOLOGY INC (ZIOP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
ZIOP Technical Analysis
ZIOP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZIOP. Both the profitability and financial health of ZIOP have multiple concerns.
ZIOP Financial Highlights
Over the last trailing twelve months ZIOP reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -22543.47% | ||
| ROA | -78.87% | ||
| ROE | N/A | ||
| Debt/Equity | 0.18 |
ZIOP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to ZIOP. The Buy consensus is the average rating of analysts ratings from 13 analysts.